VP of Marketing, Life Sciences & Clinical Markets

NanoString Technologies
Job Location
530 Fairview Ave N.
Seattle, WA 98109
Competitive Comp

Base, Bonus, Stock Options, ESPP, Matching 401K, PTO, and much more.

Job Description


It is a unique time in oncology research, diagnostics and treatment. Paradigms are changing and the regulatory environment is in flux. Clinical trials in cancer immunotherapy have seen unprecedented responses in previously intractable diseases, such as metastatic melanoma. Large pharmaceutical companies are embracing entirely different ways of treating cancer in their development programs. These new approaches to treatment don’t work for all and researchers are also racing to understand why some patients respond and other do not. The hunt is also on for new biomarkers and new types of tools and diagnostics are in demand and will emerge. The opportunity for NanoString at this time is unprecedented. We are now looking for an exceptional marketing leader to join our team as Vice President Marketing and help us continue to drive growth with a tremendously exciting, emerging portfolio in oncology, clinical markets and basic research.

Position Summary:

The VP Marketing will report to the S.VP and GM Life Sciences. The position-holder will be responsible for leading and executing product strategy and providing marketing oversight of the company’s instrumentation, reagents and informatics portfolio for the research and clinical markets, with a particular emphasis in oncology. The VP Marketing will interface extensively with the global sales team, R&D leads, the S.VP Corporate and Business Development and CEO. The marketing leader will also manage an established marketing and marketing communications team, located at the company’s offices in Seattle.


  • Driving NanoString’s Life Science product portfolio, particularly in the emerging oncology field.
  • Managing direct reports and team development including: people hiring, performance management, team building, annual goal setting and career development.
  • Leading the product management team from product concept to post launch evaluation through NanoString’s product life cycle process in partnership with the development and manufacturing teams.
  • Collaborating with the leaders of the R&D and Business Development teams to help identify, define and drive new business / product opportunities and related third party collaborations with key opinion leaders and pharmaceutical partners.
  • Ensuring the team has robust, quantitative market research to support business proposals, NPD, and product positioning.
  • Partnering with R&D and working with the Marketing team to develop strategies, messaging and product enhancements to address competitive threats and position offerings versus current/emerging technologies and products.
  • Managing the life cycle and refreshment of current products to maximize growth.
  • Recommending and monitoring pricing, discounting strategy, portfolio margins, profitability and value extraction.
  • Providing unparalleled support and partnership to support an extensive global sales and operations teams.
  • Development of annual plans, budgets and sales forecasts with the Worldwide VP of Sales and Finance departments.
  • Orchestrating the businesses out-bound marketing program and sales campaigns through web development, e-media, tradeshows, white papers, press releases and other media.



Minimum of 15 years relevant marketing experience in molecular biology, genomics and related chemistries and instrumentation platforms. A minimum of 5, to 7 years of experience, at the Director / Senior Director Marketing level and substantial line management experience.

  • Global marketing experience and associated cross functional execution encompassing: generating strategic and tactical plans; forecasting; market strategy; segmentation; branding; market research; product design goals; product management; lifecycle management; portfolio planning; competitive benchmarking; pricing and go-to-market plans.
  • Substantial experience in marketing life science capital equipment; with associated grant cycles, requirements for enterprise selling and need for high value reagents/applications development.
  • The strategic capability, vision and imagination to spot emerging trends early, think ‘outside of the box’ in potential new product and business opportunities and inspire respect from the commercial, R&D, field sales and business development teams.
  • Demonstrated ability to work effectively with external constituencies such as heads of institutions, KOLs and executives, at third party companies and collaborators. Proven life sciences and industry network.
  • Proven capability in outbound marketing including working with agencies, market research organizations and specialist consultancies to clear briefs and tight deliverables.
  • Sufficient technical knowledge to interface and counterbalance the R&D team, win the respect of technical professionals within and external to the organization and to be able to lead the team in setting appropriate product and performance specifications.
  • Proven applications knowledge, and ideally commercialization of research or clinical products, in the field on oncology, or immunology.
  • BSc/MS in molecular biology, or similar discipline, in the life sciences essential. Advanced degree (MBA or PhD) preferred.
  • Strong analytical and excellent communication skills, essential to support business proposals and win the support from the team, executive leadership, CEO and Board of Directors.
About Our Organization

NanoString Technologies (NASDAQ: “NSTG”, website: “NanoString.com”) provides start-to-finish life sciences solutions for translational research in oncology, validation and in vitro diagnostics. NanoString’s nCounter Analysis System enables researchers to cost effectively profile the expression of hundreds of genes, miRNAs or CNVs simultaneously with high sensitivity and exquisite precision. A single nCounter platform, FLEX, now allows a wide variety of basic research and translational research applications as well as the company’s first in vitro diagnostic test (ProsignaTM Breast Cancer Prognostic Gene Signature Assay) on the same system.  In 2014, business growth exceeded 50%, driven by multiple growth drivers: 75% of new systems were sold for cancer research and diagnosis; 50% of new systems were sold as a dual-mode FLEX configuration and peer reviewed publications passed 600 articles. New breakthrough oncology-research consumables launched in 2014, drove annual system pull through in 2014 beyond $100K. Additionally the company commenced a new companion diagnostics business leveraging customer biomarker discoveries and a strong pharmaceutical business franchise.

NIH's Michael Lauer looks at the number of grants, their amount, and funding success rates at the agency for last year.

At Nature, Johns Hopkins' Gundula Bosch describes her graduate program that aims to get doctoral students thinking about the big picture.

Patricia Fara writes about childcare funding, and women in science and science history at NPR.

National Institute of Environmental Health Sciences researchers have visualized the career paths of former postdocs.